Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2023-04-17 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于2022年限制性股票激励计划调整回购价格并回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from a company regarding the adjustment of the repurchase price and the repurchase and cancellation of certain restricted stocks under the 2022 restricted stock incentive plan. It details the number of shares involved, the reasons for repurchase, the price adjustments, approvals by the board and supervisory committee, independent directors' opinions, and legal opinions. The document is a formal disclosure about a share repurchase and cancellation event related to stock incentives, including changes in share capital structure. It is not a full financial report, earnings release, or management discussion, but rather a specific corporate action announcement related to share transactions by the company itself. Therefore, it fits best under the category of Transaction in Own Shares (POS). The document length is about 4871 characters, which is sufficient for a detailed announcement rather than a brief notice or a report publication announcement.
2023-04-17 Chinese
公司章程（2023年04月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 迪瑞医疗科技股份有限公司 (Dirui Industrial Co., Ltd). It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, capital changes, shareholder meetings, and governance rules. The content is legal and governance-related, focusing on the company's internal rules and regulations rather than financial performance or announcements. There is no indication of financial statements, audit reports, earnings data, or meeting results. The document is comprehensive and lengthy (15,000 characters), indicating it is the full text of the company's Articles of Association. Therefore, it fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-04-17 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年第一季度报告" which translates to "2023 First Quarter Report". It contains detailed financial data including balance sheets, income statements, cash flow statements, and explanations of financial changes for the first quarter of 2023. It explicitly states that the report is unaudited and covers a period shorter than a full fiscal year (quarterly). The content includes comprehensive financial statements and analysis, which fits the definition of an Interim / Quarterly Report (IR). The document length is over 12,000 characters, indicating it is the full report, not just an announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2023-04-17 Chinese
北京国枫律师事务所关于迪瑞医疗科技股份有限公司2022年限制性股票激励计划调整回购价格并回购注销部分限制性股票相关事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the repurchase price and repurchase cancellation of certain restricted stocks under the 2022 restricted stock incentive plan of a company. It details the legal compliance, approval procedures, and specific matters related to the stock repurchase and cancellation. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital/financing activity (stock repurchase and cancellation). Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is a substantive legal opinion rather than a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2023-04-17 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the eighth meeting of the fifth board of directors of Dirui Medical Technology Co., Ltd. It includes approvals of various reports and proposals related to the 2022 fiscal year, such as the general manager's work report, board work report, financial report, profit distribution plan, internal control self-evaluation report, and amendments to company articles. It also mentions the upcoming 2022 annual general meeting to approve these matters. The document is a formal announcement of board meeting decisions rather than the reports themselves. It references that the full reports and detailed documents are available on an external website (cninfo.com.cn). The document length is 4646 characters, which is relatively short and mainly summarizes resolutions and voting results. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement of board meeting resolutions and related corporate governance matters, not the full annual report or financial statements themselves.
2023-04-17 Chinese
2022年度监事会工作报告
Board/Management Information Classification · 85% confidence The document is titled '2022 年度监事会工作报告' which translates to '2022 Supervisory Board Work Report' of the company. It details the supervisory board's activities, meetings, opinions on company operations, financial status, internal controls, and plans for 2023. It is a comprehensive report on the supervisory board's oversight and governance activities for the year 2022. The document is 3786 characters long, which is relatively short but contains substantive content about the supervisory board's work rather than just an announcement or summary. It is not an annual report (10-K), audit report (AR), or interim report (IR) but rather a management or governance-related report. Given the content focuses on supervisory board activities and governance oversight, it fits best under Board/Management Information (MANG).
2023-04-17 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.